Back to Education Zone

touchCONGRESS Webinar

Continuing the conversation in advanced breast cancer from ESMO 2018

Introduction

Stay up-to-date with the latest advances in advanced breast cancer with our expert summary from the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, 19–23 October 2018.

Dr. Javier Cortés (Ramón y Cajal University Hospital, Madrid, Spain) reviews the most pertinent emerging data presented at ESMO 2018 and discusses their potential impact on everyday clinical practice.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching this touchCONGRESS Webinar, you should:

 

  • Recognize the challenges physicians face in the management of advanced breast cancer, with a focus on HR+/HER2- disease.
  • Be aware of key clinical data presented at ESMO 2018 for advanced breast cancer, including CDK4/6 inhibitors and other novel therapies.
  • Understand the impact that these data may have for optimizing treatment selection and patient outcomes in daily clinical practice.

Clinical Spotlight

  • Where are we now with the current management of HR+/HER2- advanced breast cancer? Focus on challenges for optimizing treatment sequencing.
  • What new data for CDK4/6 inhibitors were presented at ESMO 2018? Focus on efficacy and securing optimal cancer care.
  • What other breaking data with novel therapies for advanced breast cancer were presented at ESMO 2018? Focus on the future treatment landscape.

Please feedback on this touchCONGRESS Webinar on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).

Doctor Javier Cortés

Javier Cortés received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specializing in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associate Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he worked in the Department of Medical Oncology at the Hospital Vall d’Hebron, Barcelona, where he was Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in breast cancer with a special interest in new drugs development. Dr Cortés was the Head of the Breast Cancer Program and the Melanoma Unit from July 2006 to August 2015. From September 2015, he has been Head of the Breast Cancer and Gynaecological Tumours at Ramon y Cajal University Hospital in Madrid, Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology, and Head of the Breast Cancer Program, IOB Institute of Oncology, Madrid and Barcelona, Spain.

In addition to his medical specialties, he has two master’s degrees in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research Methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.

Dr Cortés is the author of more than 200 publications, especially regarding breast tumours and new drugs and has made more than 500 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.

Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), American Association for Cancer research (AACR) and a member of the Scientific Committee of the European Society of Medical Oncology.

Disclosures: Honoraria from Roche, Novartis, Eisai, Celgene and Pfizer. Consulting/advisor for Roche, Celgene, AztraZeneca, Cellestia Biotech, Biothera and Merus.

touchCONGRESS Expert Opinions

Watch a series of internationally renowned clinical specialists from Europe and Japan discuss key clinical data for advanced breast cancer from ESMO 2018 and their potential implications for optimizing patient outcomes from both global and regional perspectives.

Watch Now

touchCONGRESS Expert Forum

Watch a group of leading advanced breast cancer specialists from Europe consider how to optimize outcomes for patients with HR+/HER2- disease in the era of CDK4/6 inhibition.

Watch Now